点击显示 收起
众所周知，生物标记物的应用大大促进了医药产业的研究发展。然而其在儿童用药领域的发展却不尽如人意。为了能够促进儿童医药疾病研究的发展，国家卫生研究院（National Institutes of Health）决定赞助一些用于儿童疾病研究的生物标记物项目。在这份资助声明中，NIH认为用于儿童的哮喘、糖尿病等疾病的生物标记物都与成人有所差异，需要特殊对待才能赶上目前在该领域的差距。
详细英文报道：
In an effort to advance drug and disease research in children, a unit of the National Institutes of Health aims to fund studies of biomarkers of adult ailments for use in pediatric patients.
Like it or not, scientists study biomarkers for adult patients far more often than their pediatric counterparts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) wants to remedy the imbalance of attention given to adult biomarker research with new funding opportunities for researchers with plans to study biomarkers for a variety of uses in children.
In a funding announcement, the NIH unit highlighted the fact that biomarkers related to diseases such as asthma, diabetes and epilepsy require additional study for use with children, whose developing systems often present markers differently than do those of adults with the same ailments. The agency has opened the funding opportunity to all manner of pediatric markers, including those used for diagnosis, prognosis, clinical trial endpoints, gauging toxicity and predicting treatment responses.
As GenomeWeb noted, the agency debuted the program for advancing biomarkers from adult studies to pediatric investigations two years ago to improve development of therapies for children. The NIH aims to lure scientists into tackling therapeutic needs of kids, who are often an afterthought in drug research that has historically put adult patients first.
The research community has been reeling from underfunded NIH budgets, and that problem is likely to persist as the agency has already projected a 5% drop in spending. Yet scientists with bright ideas for translating useful biomarkers from adult studies for use in kids could find funding through this grant opportunity.